Chichirelo-Konstantynovych, K. D.     Community-acquired pneumonia associated with cytomegalovirus persistence: prevalence and peculiarities of clinical course [] / K. D. Chichirelo-Konstantynovych // Запорож. мед. журн. - 2018. - Том 20, N 3. - С. 366-370 MeSH-главная: ПНЕВМОНИЯ -- PNEUMONIA (диагностика, лекарственная терапия, этиология) ЦИТОМЕГАЛОВИРУС -- CYTOMEGALOVIRUS (действие лекарственных препаратов, патогенность) АНТИТЕЛА -- ANTIBODIES (кровь) Аннотация: The article discusses the problem of cytomegaloviral persistence asymptomatic course among young patients with community-acquired pneumonia and in healthy population group based on specific immunoglobulins M and G appearance in blood andantibody avidity value (the duration of persistent). The connection between viral persistence and prognosis of community-acquiredpneumonia course (by pneumonia severity index in PORT) is also recognized. Aim of the scientific work is to study the prevalence of cytomegaloviral persistence among young patients with community-acquired pneumonia for optimization the plan of clinical examination and prognosis for this patient category. Materials and methods. One hundred and five patients with community-acquired pneumonia and 61 healthy individuals (aged from 18 to 44 years) were examined for cytomegaloviral biomarkers (CMV IgG, CMV IgG avidity) and by PORT-scale. Positiveresult for viral persistence was compared with gender, age subtypes and pneumonia severity index in both groups. Results. Cytomegaloviral persistence prevalence rate among patients with community-acquired pneumonia was 48.2 % versus 20.5 % among healthy individuals (P = 0.003). The patients with community-acquired pneumonia had higher CMV IgG avidityvalue (P = 0.007), it was more common for female patients (P = 0.043; ?2 = 8.164). The cytomegaloviral persistence prevalenceincreased with age (P = 0.045) and correlated with pneumonia severity index according to PORT-scale (P 0.0001). Conclusions. The patients with community-acquired pneumonia differ in significantly higher cytomegaloviral prevalence rate (P 0.05). Экз-ры: